Equities

iRhythm Technologies Inc

iRhythm Technologies Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)82.32
  • Today's Change8.33 / 11.26%
  • Shares traded536.24k
  • 1 Year change-5.11%
  • Beta1.2404
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy6
Outperform5
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Irhythm Technologies Inc have a median target of 96.00, with a high estimate of 125.00 and a low estimate of 79.00. The median estimate represents a 16.62% increase from the last price of 82.32.
High51.8%125.00
Med16.6%96.00
Low-4.0%79.00

Earnings history & estimates in USD

On Oct 30, 2024, Irhythm Technologies Inc reported 3rd quarter 2024 losses of -1.26 per share.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate-23.84%
Irhythm Technologies Inc reported annual 2023 losses of -4.04 per share on Feb 22, 2024.
Average growth rate-27.10%
More ▼

Revenue history & estimates in USD

iRhythm Technologies, Inc. had 3rd quarter 2024 revenues of 147.54m. This bettered the 146.73m consensus of the 11 analysts covering the company. This was 32.40% above the prior year's 3rd quarter results.
Average growth rate+4.44%
iRhythm Technologies, Inc. had revenues for the full year 2023 of 492.68m. This was 19.90% above the prior year's results.
Average growth rate+23.13%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.